← Leaderboards
David Maloney
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at National Center For Advancing Translational Sciences
Same institution · by research overlap
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesResearch PersonnelPublicationsPharmaceutical PreparationsPharmaceutical ChemistryNovel TherapeuticsGeneral PopulationInhibitor/AntagonistInformaticsHuman DiseaseBiologyLeadAssay DevelopmentNew TechnologyDrug DiscoveryExtramural ActivitiesBaseFosteringCollaborationsCommunitiesGenomicsHigh Throughput ScreeningDrug DevelopmentScreening
Grant awards (24)
Identification of Inhibitors of Myosin Polymerization as Novel Therapies for Asthma$226,982
ZIA · FY2016 · TR · contact PI
Inhibitors of USP1$226,982
ZIA · FY2016 · TR · contact PI
Inhibitors of p53-S100B interaction for melanoma$226,982
ZIA · FY2016 · TR · contact PI
Selective Inhibitors of ALDH1A1$226,982
ZIA · FY2016 · TR · contact PI
12-LOX inhibitors as Potential Anti-Platelet Therapeutics$226,982
ZIA · FY2016 · TR · contact PI
Implications of 12-Lipoxygenase and NOX-1 in beta-Cell dysfunction, a potential target for Diabetes$226,982
ZIA · FY2016 · TR · contact PI
15-hLO-1 inhibitors as Potential Therapeutics Against Stroke$226,982
ZIA · FY2016 · TR · contact PI
Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents$226,982
ZIA · FY2016 · TR · contact PI
BRD4 Inhibitors as Potential Therapeutics for Oncology$226,982
ZIA · FY2016 · TR · contact PI
12-LOX inhibitors as Potential Anti-Platelet Therapeutics$114,000
ZIA · FY2015 · TR · contact PI
Implications of 12-Lipoxygenase and NOX-1 in beta-Cell dysfunction, a potential target for Diabetes$114,000
ZIA · FY2015 · TR · contact PI
15-LOX-1 inhibitors as Potential Anti-Platelet Therapeutics$114,000
ZIA · FY2015 · TR · contact PI
Inhibitors of p53-S100B interaction for melanoma$114,000
ZIA · FY2015 · TR · contact PI
Identification of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anti-cancer Agents$114,000
ZIA · FY2015 · TR · contact PI
BET Inhibitors as Therapeutics for Oncology$114,000
ZIA · FY2015 · TR · contact PI
ML199: Inhibitor of Ape1 as a Lead for Cancer Therapeutics$114,000
ZIA · FY2015 · TR · contact PI
Development of Oxadiazole-2-oxides as Therapeutic Leads Against Schistosomiasis and Hookworm Diseases$114,000
ZIA · FY2015 · TR · contact PI
Discovery of Delayed Death Inhibitors for Antimalarial Indications$114,000
ZIA · FY2015 · TR · contact PI
Small molecule inhibitors of Bloom helicase modulate chromosome stability in human cells$114,000
ZIA · FY2015 · TR · contact PI
Discovery of ML324, a JMJD2 Demethylase Epigenetic Modulator as Potential Antiviral$114,000
ZIA · FY2015 · TR · contact PI
ML267: Inhibitor of Sfp-PPTase that Attenuates Secondary Metabolism and Thwarts Bacterial Growth$114,000
ZIA · FY2015 · TR · contact PI
Discovery of Inhibitors of Human 5-Lipoxygenase and CYP51 as Anti-Fungal Leads$114,000
ZIA · FY2015 · TR · contact PI
Selective Inhibitors of ALDH1A1$114,000
ZIA · FY2015 · TR · contact PI
Assay for Inhibitors of HPGD, 15-hydroxyprostaglandin dehydrogenase$114,000
ZIA · FY2015 · TR · contact PI